KRAS and cancer: The specific observation of its impact on downstream signaling and proliferation was specifically observed in cancer cells harboring mutant KRAS. Remarkably, treatment with the drug significantly inhibited the growth of KRAS mutant tumors in mice, without eliciting any obvious adverse effects on animals [42].